Tag
3 articles
An AI-designed drug called rentosertib has shown potential in reversing biological aging markers, according to a study in Nature Biotechnology. The drug, developed by Insilico Medicine, was tested on 42 patients and demonstrated promising results in early trials.
Insilico Medicine has significantly shortened drug discovery timelines in China by combining AI with laboratory research, cutting development time to as little as nine months.
Takeda has entered a $600 million AI drug discovery collaboration with Insilico Medicine, leveraging AI to accelerate early-stage drug development across multiple therapeutic areas.
